These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36925461)

  • 1. Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin.
    Qian XJ; Wen ZM; Huang XM; Feng HJ; Lin SS; Liu YN; Li SC; Zhang Y; Peng WG; Yang JR; Zheng ZY; Zhang L; Zhang DW; Lu FM; Liu LJ; Pan WD
    World J Gastroenterol; 2023 Feb; 29(8):1359-1373. PubMed ID: 36925461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Diagnostic Model for Early Hepatitis B Virus-Related Hepatocellular Carcinoma Diagnosis.
    Li S; Liu D; Wang Q
    Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.
    Qian X; Liu Y; Wu F; Zhang S; Gong J; Nan Y; Hu B; Chen J; Zhao J; Chen X; Pan W; Dang S; Lu F
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
    Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
    Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.
    Chen Y; Yang Y; Li S; Lin M; Xie X; Shi H; Jiang Y; Zheng S; Shao H; Yang N; Lu M
    Front Public Health; 2021; 9():784718. PubMed ID: 35145947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
    Chen J; Tang D; Xu C; Niu Z; Li H; Li Y; Zhang P
    Lab Med; 2021 Jul; 52(4):381-389. PubMed ID: 33159511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.
    Ricco G; Cavallone D; Cosma C; Caviglia GP; Oliveri F; Biasiolo A; Abate ML; Plebani M; Smedile A; Bonino F; Pontisso P; Brunetto MR
    Cancer Biomark; 2018 Feb; 21(3):603-612. PubMed ID: 29278878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
    Xu F; Zhang L; He W; Song D; Ji X; Shao J
    Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
    Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
    Ekmen N; Akalin Ç; Akyildiz M
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China.
    Chi X; Jiang L; Yuan Y; Huang X; Yang X; Hochwald S; Liu J; Huang H
    BMC Gastroenterol; 2022 Apr; 22(1):202. PubMed ID: 35461226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
    Ji J; Liu L; Jiang F; Wen X; Zhang Y; Li S; Lou J; Wang Y; Liu N; Guo Q; Jia Y; Gao C
    J Clin Lab Anal; 2021 Nov; 35(11):e24013. PubMed ID: 34590755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.